There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alkermes (ALKS – Research Report), Moderna (MRNA – Research Report) and Pyxis Oncology (PYXS – Research Report) with bullish sentiments.
Alkermes (ALKS)
Jefferies analyst Akash Tewari maintained a Buy rating on Alkermes yesterday and set a price target of $45.00. The company’s shares closed last Wednesday at $25.83.
According to TipRanks.com, Tewari is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alkermes with a $33.38 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Moderna (MRNA)
Jefferies analyst Michael Yee maintained a Buy rating on Moderna yesterday and set a price target of $275.00. The company’s shares closed last Wednesday at $148.18.
According to TipRanks.com, Yee is a 2-star analyst with an average return of
Moderna has an analyst consensus of Moderate Buy, with a price target consensus of $222.86, implying a 45.4% upside from current levels. In a report issued on March 13, Cowen & Co. also upgraded the stock to Buy with a $180.00 price target.
Pyxis Oncology (PYXS)
Jefferies analyst Eun Yang maintained a Buy rating on Pyxis Oncology yesterday and set a price target of $16.00. The company’s shares closed last Wednesday at $2.20, close to its 52-week low of $1.10.
According to TipRanks.com, Yang is a 4-star analyst with an average return of
Pyxis Oncology has an analyst consensus of Moderate Buy, with a price target consensus of $12.50, which is a 448.2% upside from current levels. In a report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $9.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALKS:
